Introduction to Mounjaro
In a significant move, Eli Lilly has launched its groundbreaking weight-loss and diabetes management drug, Mounjaro (tirzepatide), in India. This once-weekly injectable medication is the first major GLP-1 receptor agonist to enter the Indian market, beating rival Novo Nordisk's anticipated launch of Wegovy. Mounjaro is priced at ₹4,375 for a 5 mg vial and ₹3,500 for a 2.5 mg vial, making it more affordable for Indian patients compared to its U.S. pricing.
The Indian Market Opportunity
India, with over 100 million obese adults and 101 million diabetics, presents a substantial market for weight-loss and diabetes treatments. The country's obesity crisis is projected to worsen, with estimates suggesting that by 2050, 440 million people could be obese, placing a massive